Coronavirus TV: Vaccine Expertise And R&D In India
Vibha Ravi, the Mumbai-based subeditor within Scrip's APAC content team, talks about how Indian firms are stepping up to the challenge of developing a coronavirus vaccine in this episode of Pharma Intelligence's Coronavirus TV.
You may also be interested in...
Private US firm Refana, which expects its first commercial foray through a COVID-19 vaccine it will develop with Panacea Biotec, has obtained an option to acquire a stake in the Indian firm, with marketing rights to be split with the partners' 50:50 joint venture.
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.